Pre-filled Syringe
IBSA laboratories have developed PEROVIAL®, a product intended for men affected by Peyronie’s disease.
Hyaluronic acid is a predominant GAG – glycosaminoglycan of the connective tissue – and is present at high concentrations in the tunica albuginea. Hyaluronic acid is composed of glucuronic acid and N-acetylglucosamine, held together by β-glycosidic bonds. At physiological pH, hyaluronic acid is highly polarized and maintains hydration, turgor, plasticity and viscosity in the amorphous connective matrix. Thanks to its antioxidant and antifibrotic effects, there is a reduction in plaque-related symptoms and a limitation of growth.
The pre-filled syringe technology simplifies the administration of the product, perfectly sterile, reducing the risk of errors, consequently improving safety.
PEROVIAL® is composed of a buffered saline solution of hyaluronic acid sodium salt.
PEROVIAL® contains 0.8% highly purified hyaluronic acid sodium salt with a molecular weight between 800 and 1.200 kDalton.
Want to know more about the technology?
Contact usWant to know who is IBSA?
DISCOVER MOREDo you want to know more?
Fill the form to contact us

IBSA Business Development
Since 2018, there has been a new Department in IBSA fully dedicated to Business Development, Licensing activities and CDMO projects. Licensing The Business Development Dept. is constantly looking for partners and international distributors for licensing agreements in countries where IBSA does not operate directly with its branches. IBSA is focused on strategic collaborations to achieve a common goal while sharing responsibilities, resources, risks and rewards. Close ties with local distributors are crucial for IBSA to grow at an international level. The Business Development Dept. also evaluates licensing-in opportunities for the expansion of product portfolio.